Celularity Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Celularity Inc. on April 16, 2025. The report addresses a regulatory compliance issue regarding the company's failure to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2024.
Key Financial Metrics
The filing text does not provide specific financial data, including revenue, profit, cash flow, margins, debt, or liquidity metrics. This document focuses exclusively on listing compliance status.
Material Changes and Events
- Delisting Notice: On April 16, 2025, Nasdaq issued formal notice that Celularity failed to comply with Listing Rule 5250(c)(1) due to the late filing of its 2024 Form 10-K.
- Trading Status: The notice has no immediate effect on trading; Class A Common Stock (CELU) and Warrants (CELUW) continue to trade on the Nasdaq Capital Market.
- Compliance Timeline: Celularity must submit a plan to regain compliance within 60 calendar days (by June 16, 2025). If accepted, the company has until October 13, 2025, to implement the plan.
Outlook, Risks, and Management Commentary
Management states that the company is actively working to file the 2024 Form 10-K "imminently." While Celularity intends to submit a compliance plan if necessary, the filing explicitly states there can be no assurance that the company will regain compliance within the allotted period. If the deficiency is not cured, Nasdaq may notify the company that its stock is subject to delisting.
Investor Verification Checklist
- Verify the actual filing date of the 2024 Form 10-K to confirm if the "imminent" filing expectation was met.
- Monitor for the submission of a formal compliance plan to Nasdaq by June 16, 2025.
- Review the 2024 Form 10-K once filed to assess the underlying financial reasons for the delay and the company's current liquidity position.
- Check for any subsequent Nasdaq communications regarding the acceptance or rejection of the compliance plan.